

Ola Bratt's Curriculum vitae

1. Personal details and contact information

Full name: Björn Ola Bratt
Born: Lund, Sweden, 16th September, 1963

Academic affiliation

Professor of Clinical Cancer Epidemiology
Institute of Clinical Sciences
Sahlgrenska Academy
University of Gothenburg
413 46 Göteborg
Sweden
E-mail: ola.bratt@gu.se
Phone: +46-702763233

Hospital affiliation:

Department of Urology
Prostate Cancer Centre
Sahlgrenska University Hospital
413 46 Göteborg
Sweden
E-mail: ola.bratt@vgregion.se
Phone (secretary): +46-(0)31-342 92 80

Home address:

Nordenskiöldsgatan 21B
413 09 Göteborg
Sweden
Mobile phone: +46-(0)70-2763233
E-mail: ola.bratt@hotmail.com

2. Licenses to practice

Licensed physician in Sweden (1995)
Licensed urological surgeon in Sweden (2002)
Licensed physician and urological surgeon in the UK (2014, GMC: 7471505)

3. Memberships

Swedish Urological Society
European Association of Urology

4. Medical qualifications

Specialist certificate (urology), General Medical Counsel, UK: March 2014
Licence to practice, General Medical Counsel, United Kingdom: March 2014
Fellow of the European Board of Urology: 2004
Specialist certificate (urology), Swedish National Board of Health and Welfare: 2002
Licensed physician, Swedish National Board of Health and Welfare: 1995
Graduation, Medical School, University of Lund, Sweden: 1991
Assistant nurse (undersköterska, 1 års Vårdiriktad kompletteringskurs): 1983

5. Academic qualifications

Full Professor, Sahlgrenska Academy, Gothenburg University, February 2021
Adjunct Professor, Sahlgrenska Academy, Gothenburg University, 2017
Deemed qualified for a professorship at Copenhagen University, 2016
Associate Professor, Medical Faculty, Lund University, 2003
Doctor of Philosophy (Ph.D.), Medical Faculty, Lund University, 1999
Medical Doctor (M.D.), Lund University, 1991

6. Academic positions

Professor of Clinical Cancer Epidemiology, Sahlgrenska Academy, Gothenburg University, Sweden, February 2021 -
Adjunct Professor of Urology, Sahlgrenska Academy, Gothenburg University 2018 – 2021
Visiting Professor, Nuffield Department of Surgical Sciences, University of Oxford, UK, April 2014 to March 2015
Senior Lecturer, Medical School, Lund University, Sweden: January 2012 to May 2014

7. Clinical employment history

Consultant Urological Surgeon, Sahlgrenska University Hospital, Sweden, September 2017 to present
Consultant Urological Surgeon, Cambridge University Hospitals NHS Trust, UK, January 2015 to May 2017
Honorary Consultant Urological Surgeon, Oxford University Hospitals NHS Trust, UK, April 2014 to December 2014
Consultant urological surgeon, Helsingborg Hospital, Sweden November 2008 to May 2014
Consultant urological surgeon, Lund University Hospital January 2004 to November 2008
Urology Specialist, Helsingborg Hospital September 2002 to December 2003
Urology specialty training, Lund University Hospital & Helsingborg Hospital April 1995 to September 2002,
House officer (internship), Helsingborg Hospital and primary care March 1993 to April 1995
House officer (locum), Urology & Oncology, Lund University Hospital June 1991 to March 1993
Physician, Cancer Rehabilitation, Lydiagården, 1999 - 2006 (16 separate weeks).
Assistant nurse: ENT Theatres 12 months 1983-4, Neurosurgical ward 6 months 1984-5, Medical Intensive Care Unit 6 months 1988.

8. Research and clinical trial experience:

Chairman, Swedish Consortium for Research on Organised Prostate Cancer Testing, 2022 -
Principal investigator, Diagnostic Outcomes and Socioeconomic Inequity in Swedish Organised Prostate Cancer Testing (National multicentre research group), 2023 -
Site investigator, PSMA/PET-DT guided treatment of recurrence after radical prostatectomy (RCT): 2020 -
Principal investigator, Study of Active Monitoring of Low-Risk Prostate Cancer in Sweden (SAMS), a multi-centre RCT on early prostate cancer: 2010 – (ref 40)

Ola Bratt's CV on the 28th April 2024

Principal investigator for clinical research on the utility of PET/CT for staging of prostate cancer, Lund university: 2007 - 2014.

Principal investigator, phase I-II multicentre study of Tasquinomod for metastatic prostate cancer, 2007 – 2008 (ref 23)

Steering committee member, PCBaSE Sweden (epidemiological research based on the National Prostate Cancer Register), 2009 –

Steering committee member, PCASSt/SPCG-17 (international RCT, active surveillance of prostate cancer) 2015 –

Steering committee member, PROPER (RCT on postoperative radiotherapy after surgery for prostate cancer), 2021 –

Chairman, Swedish Consortium for Research on Organised Prostate Cancer Testing, 2022 -

Co-investigator, 9 clinical trials phase I - III, 1996 –

GCP course, Lund Univ 2004. Most recent refresher Gothenburg Univ 2020.

Chairman, Data Monitoring and Safety Committee, SPCG-14 (RCT on chemotherapy for prostate cancer), 2017 - 2022

Chairman, Data Monitoring and Safety Committee, Stockholm3-MR (RCT on MRI and biomarkers for high grade prostate cancer detection), 2018-2021

Chairman, Data Monitoring and Safety Committee, ProScreen (Finnish prostate cancer screening RCT), 2018-

Chairman, Data Monitoring and Safety Committee, PRIS (Swedish focal PCa treatment RCT), 2021-

Advisory and Editorial Board for scientific journals

Editorial Board member: European Urology Oncology 2020 –

Editorial Board member: BJU International 2022 –

Advisory Board Member, Scandinavian Journal of Urology, 2021 –

Advisory Board Member, Acta Oncologica, 2015 -

Advisory Board Member, Onkologi i Sverige, 2014 –

Advisory urology expert, Läkartidningen, (Swedish Medical Journal) 2008 –

Reviewer for scientific journals:

Regularly: European Urology (since 1999, > 140 reviews, Reviewer of the Year 2016), European Urology Oncology (> 50 reviews, named among top-10 reviewers 2018 – 2019), The Journal of Urology, British Journal of Urology International, and Scandinavian Journal of Urology.

Occasionally: New England Journal of Medicine, JAMA, The BMJ, BMJ Open, Lancet Oncology, Lancet Infectious Diseases, Journal of Clinical Oncology, Nature Reviews Urology, Nature Scientific Reports, British Journal of Cancer, PLoS Medicine, BMC Cancer, BMC Medicine, BMC Urology, Cancer, Epidemiology, European Urology Focus, Eur Urol Open Sci, Scandinavian Journal of Urology and Nephrology, Acta Oncologica, Cancers, Translational Andrology and Urology, Journal of Community Genetics, Clinical Investigation, Urology Case Reports, International Journal of Urology and Nephrology, Urology Journal, Urology Reviews, Journal of Oncology, Clinics of Oncology, International Brazilian J Urol, Asian J Andrology, Clinical Radiology, Saudi Journal of Medicine and Medical Sciences, and Läkartidningen (the Swedish Medical Journal).

9. Research Funding (only grants > 10,000 EUR are listed)

Swedish Cancer Foundation: 70 000 EUR/ year for the SAMS trial 2011 - 2023

Gothenburg University Hospital (ALF): 90,000 EUR per year 2019 – 2021

Gothenburg University Hospital (ALF): 50,000 EUR per year 2022 – 2024

Regional Research Funding, Västra Götalandsregionen: 30,000 EUR 2022 – 2023
Swedish Cancer Foundation: 3 research months per year 2009 - 2018
Torsten Gersters Research Foundation: 80 000 EUR for the SAMS trial 2017
Gorthons stiftelse: 70 000 EUR for the SAMS trial 2009

10. Publications (see appendix)

11. Activity at conferences and non-academic courses

Organising committee member and lecturer. Annual 4-day course on register-based cancer research, Regional Cancer Centre West, 2023 -

Course coordinator, moderator and speaker at the annual 3-day course on prostate cancer for qualified Swedish oncologists and urologists 2004 to 2021 (15 courses)

Course coordinator, moderator and speaker at the annual 2-day course urological oncology for qualified oncologists and urologists (Arild, Sweden): 2009 to present (12 courses)

Course coordinator, moderator and speaker at the annual 5-day course on prostate cancer and benign prostatic hyperplasia for urologists ("Kalmarunionen", Kalmar, Sweden): 1998 - 2012 (11 courses)

Course coordinator, moderator and speaker at an annual 2-day course for prostate cancer nurse specialists, Steningevik, Sweden: 1999-2010 + 2018-19

Chairman for the Cambridge Prostate MRI and Biopsy Course (1 day), Gothenburg May 2022 and Stockholm May 2023.

Chairman for the MRI and biopsy whole-day session at the 10th International Symposium on Focal Therapy and Imaging in Prostate Cancer, February 2018

Faculty member and speaker, Nordic Advanced Prostate Cancer Camp, an annual 2-day course for young oncologists and urologists: 2017

Moderator and/or invited speaker at approximately 20 international and 45 national meetings in addition to those mentioned above, e.g. invited speaker at the EUA Prostate Cancer Meeting in Milano 2018, the Nordic Urological Association's meeting in Helsinki 2022, the Prostaforum conference in Prague 2022, the EU Conference on Cancer: Equity, Excellence and Innovation in 2023, the EAU meeting in Milano 2023, and the Nordic Urological Association's meeting in Bergen 2023.

12. Audits

Inspector of Swedish urological residency programs for the Swedish Urology Association and the Swedish Medical Society 2003 - 2014

13. Teaching courses

Postgraduate Course in Teaching Clinical Communication, a 2-day course at Cambridge University, November 2016

Perspectives on learning, a 2-week course for teachers at the Faculty of Medicine, Lund University, October 2016

Teaching Evidence Based Medicine, a 1-week course at the University of Oxford, 2014.

The mandatory courses for promotion to Associate Professor at the Faculty of Medicine, Lund University (6 weeks in total, 1998-2002): Presentation skills, Problem based learning, The Case Method, Encounters with media, Clinical supervision, Supervising medical students, Research supervision

14. Academic teaching, supervision, and various commissions

Examinator and lead lecturer, Clinical Research School for PhD Students (30 ECTS), Gothenburg University, 2021 –

Course coordinator, Medical Research Methodology (30 ECTS), Lund University, 2009-14

Course coordinator, Urology, Medical Program Helsingborg, Lund University, 2011 - 2014

Ola Bratt's CV on the 28th April 2024

Course coordinator, Medical Science for Residents (annual 2½ weeks) 2010 – 2014

Organizing committee member (1 of 3): Swedish Meeting on Prostate Cancer Research, Gothenburg University, 3-4th February 2020

Principal supervisor of Ph.D. student Henrik Kjölhede 2008 - 2014 (Lund University)

Thesis "Diagnosing prostate cancer metastases" (defended 22nd Nov 2014)

Principal supervisor of Ph.D. student L Svensson 2018 – 2023 (Gothenburg Univ)

Project "Psychosocial consequences of prostate cancer screening"

Principal supervisor of Ph.D. student Joakim Örtegren 2019 - (Gothenburg Univ)

Project "Prostate biopsy: aspects of sampling and infectious complications"

Principal supervisor of Ph.D. student J Maljkovic 2019 - (Gothenburg Univ)

Project: "Active surveillance for low-risk prostate cancer"

Principal supervisor of Ph.D. student Emil Järbur 2020 – (Gothenburg Univ)

Project "Organised prostate cancer testing"

Assisting supervisor of Ph.D. student Andreas Forsvall (Lund Univ), 2015 - 2022

Project: Development of a new method for prostate biopsy

Assisting supervisor of Ph.D. student Ola Christiansen, (Oslo University), 2016 - 2022

Project: Database for patients treated with radical prostatectomy.

Assisting supervisor of Ph.D. student Charlotte Alvebratt, 2020 – (Gothenburg Univ)

Project: Epidemiological studies of metastatic prostate cancer

Mentor for Ph.D. student Snejana Nuaman 2008 – 2014 (Lund University)

Supervisor of Catarina Lindell, Research methodology for PhD students (30 ECTS):

"Biofeedback vid bäckenbottenträning efter radikal prostatektomi – en randomiserad studie", Lund University 2008-9

Supervisor of Anna-Clara Benoni's Master Degree project: "Ultrasensitivt PSA och postoperativ strålbehandling vid prostatacancer (30 ECTS) 2007-8

Supervisor of Martin Diva's Master Degree project: "Real world effects and side effect of abiraterone and enzalutamide for metastatic castration resistant prostate cancer", Gothenburg University (30 ECTS) 2018-2019

Supervisor of Victoria Huang's Master Degree project: "Value of a second PSA test in the clinical prostate cancer diagnostic pathway", Gothenburg Uni (30 ECTS) 2021 - 2022

Supervisor of Hang Dang's Master Degree project: " Value of a second PSA test in the organized prostate cancer testing", Gothenburg University (30 ECTS) 2021 - 2022

Supervisor of Emelie Abrahamsson's Specialty project: "Rationale for subclassification of high risk prostate cancer", Sahlgrenska University Hospital, 2020

Supervisor of Mikael Redsäter's Specialty project: "Identifying a subgroup av high risk prostate cancer patients that does not need a bone scan", Sahlgrenska University Hospital, 2020

Clinical supervisor, urology resident Violeta Karadacic, Dept. Urology, Lund University Hospital 2006 – 2008

Clinical supervisor, urology resident Mohammed Alfwazan, Dept. Urology, Gothenburg University Hospital 2018 –

Mentor for 3 house officers, Helsingborg Hospital 1999 - 2003

Lecturer, Medical Program (330 ECTS), Gothenburg University, 2017 –

Lecturer, Medical Program (330 ECTS), Lund Univ., 1996-1999 & 2004-2008, 2013-14

Lecturer, Specialist Urology Nursing (40 ECTS), Lund University, 2002 - 2023

Lecturer, Nurse Program (180 ECTS), Lund University, 2002-2008

Lecturer, Clinical Research School for PhD Students (30 ECTS), Gothenburg University, 2021 –

Main opponent at Ph.D. dissertations: 7 times:

A Waldman, Urology, Karolinska Institute, Stockholm, 2005

O Andrén, Urology, Örebro University, 2008

Ola Bratt's CV on the 28th April 2024

A Kjällman, Urology, Karolinska Institute, Stockholm, 2010
D Bentzon, Urology, Århus University, 2012
B Lazarevic, Urology, Oslo University, 2012
L Kanerva, Urology, Helsinki University, 2017
N Klemann, Urology, Copenhagen University, 2017
S M Kawa, Urology, Copenhagen University, 2022

External reviewer at Ph.D. dissertation: 2 times
S Pakkanen, Urology, Tampere University 2010
I Ingimarsdóttir, Urology, Reykjavik University 2017

Scientific committee member at Ph.D. dissertations: 41 times in Sweden, 2004 –

Member of the permanent group of Ph.D. dissertation committee members, Sahlgrenska Academy, Gothenburg University, July 2020 -

External reviewer for higher academic positions: Karolinska Institute 2019; University of Cambridge UK 2019, Bristol University 2022, University of Lund 2022, University of Uppsala 2022, University of Örebro 2022.

External reviewer of applications for Clinical Centre of Excellence: Odense University Hospital, Denmark, 2020

Grant application reviewer:

INCa (French National Cancer Institute) 2010
Segefalks Stiftelse for medical research 2011-15
Cancer Research UK 2015-17& 2023
Karolinska Institute 2017
Dutch Cancer Society 2020
West Swedish Prostate Cancer Society Research Fund 2020
Irish Health Research Board 2023
Swedish Cancer Foundation (Cancerfonden): 2021 –
Karolinska Institute Research Fund: 2021 – (chairman since 2023)

15. Management experience

Member of the Leading Group, Dept Urology, Sahlgrenska Uni Hosp, 2019 -
Clinical Lead of Urology, Helsingborg Hospital 2010 – 2013
Deputy Head of the Dept. of Urology, Lund University Hospital 2005 – 2007
Clinical Lead of the Oncological Surgery Team, Department of Urology, Lund University Hospital 2004 – 2008
For academic management, see 14a-c

16. Procedures (independent, primary surgeon):

Radical prostatectomies: 1,000 (250 open, 750 robotic)
Prostate brachytherapy implants: 100
Transurethral surgery (prostatic hyperplasia, bladder tumours, etc): > 500
Endoscopic surgery of the upper urinary tract: > 100
Penile and scrotal surgery: > 100
Open renal surgery: 20
Bowel surgery: 10
Cystectomies: 3
Cystostocopy, transurethral ultrasound with prostatic biopies: > 3,000
Transperineal template prostate biopsy +/- MR/US fusion (in UK & Sweden): 40

17. Awards

The Swedish Prostate Cancer Patient Society's honorary prize 2017 (the first ever): "Ola Bratt has through his dedication, didactic precision and scientific mind since long been a leading star in prostate cancer care. He has led and participated in numerous research projects, developed the care of men with prostate cancer, and been active in the debate in professional as well as in general media. Ola Bratt's international experience has further enriched his holistic grip on the prostate cancer patients and on health care. Always with the patients' interest in mind he is an important force for improving the care of men with prostate cancer."

Reviewer of the Year 2016, European Urology

Rewarded the Ben Turpin Prize 1999. This prize is awarded annually to a Swedish urologist who has made prominent clinical achievements and is good colleague.

18. Other activities:

Registry holder of the Swedish Quality Registry for Organised Prostate Cancer Testing: 2023 –
Steering group member, Regional Organised Prostate Cancer Testing at RCC West: 2019 –
Regional Prostate Cancer Process Manager, Regional Cancer Centre West: January 2019 - 2021
Chairman of the Swedish National Coordination Group for Organised Prostate Cancer Testing,
Confederation of Regional Cancer Centres (RCC i samverkan): 2018 -
Chairman, Swedish National Prostate Cancer Guidelines Group: 2011 – 2015 & 2019 – 2023
Urology expert, Health and Social Care Inspectorate (IVO): 2016 –
Chairman, PrCa Diagnostics/screening Group, National Board of Health & Welfare: 2010 –
Member of the Prostate Cancer Expert Group, National Board of Health & Welfare: 2004 –
Steering committee member, National Prostate Cancer Register: 2004 – 2023
Member of the Reference Group for National Screening Programs, National Board of Health and
Welfare, 2012 - 2014
External reviewer of the systematic assessment “Molecular Diagnostic Tests for Men at Higher
Probability for Prostate Cancer” made by the Swedish Agency for Health Technology Assessment
and Assessment of Social Services (SBU) , 2011
Editor of the South Swedish Prostate Cancer Guidelines, 2004 - 2013
Chairman of the South Swedish Prostate Cancer Group, 2004 – 2013
Secretary of the South Swedish Prostate Cancer Group, 1996 - 2004
Member of the Expert Council of the Swedish Cancer Foundation, 2005-
Member of the Educational Committee of the Swedish Society of Urology 1998 – 2001
Member of the founding board, South Swedish Society of Palliative Care, 1998 – 2000
Chairman of the Swedish Society of Residents in Urology, 2000-2002
Secretary of the Swedish Society of Residents in Urology, 1996-2000
Secretary of the European Society of Residents in Urology, 1997-1999
Swedish Communication Officer to the European Society of Residents in Urology, 1995-9
Board member, Lydiagården Cancer Rehabilitation, 2009 to 2013.

22. Publications

Original research articles

1. **Bratt O**, Elfving P... and Lundgren R: Morbidity of pelvic lymphadenectomy, radical prostatectomy, and external radiotherapy in patients with localised prostatic cancer. *Scand J Urol Nephrol* 28:265-271, 1994
2. **Bratt O**, ..., and Lundgren R: Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. *Urology* 47:218-224, 1996
3. **Bratt O**, Kristoffersson U, Lundgren R, Olsson H: Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. *Urology* 50:360, 1997.
4. **Bratt O**, ... and Olsson H. The risk for malignant tumours in first-degree relatives of men with early onset prostate cancer. A population-based cohort study. *Eur J Cancer*, 33:2237-40, 1997.
5. **Bratt O**, Kristoffersson U, Olsson H, and Lundgren R. The clinical cause of early onset prostate cancer with special reference to family history as a prognostic factor. *Eur Urol* 34:19-24, 1998.
6. **Bratt O**, Kristoffersson U, Olsson H, and Lundgren R. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. *Eur J Cancer* 35:272-277, 1999.

Ola Bratt's CV on the 28th April 2024

7. **Bratt O**, Borg Å, Kristoffersson U, Lundgren R, Zhang Q-X, and Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. *Br J Cancer*, 81:672-6, 1999.
8. **Bratt O**, Damber J-E, Emanuelsson M, Kristoffersson U, Lundgren R, Olsson H, and Grönberg H. Risk perception, adherence to screening, and interest in genetic testing among unaffected men in families with hereditary prostate cancer. *Eur J Cancer*, 36:235-241, 2000.
9. Saramäki OR, Savinainen KJ, **Bratt O**, and Visakorpi T. Amplification of hypoxia-inducible factor 1-alfa gene in prostate cancer. *Cancer Genet Cytogenet*, 128:31-34, 2001.
10. Saramäki O, Willi N, **Bratt O**, ..., and Visakorpi T. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. *Am J Pathol*, 159: 2089-2094, 2001
11. Savinainen KJ, Saramäki O, Linja M, **Bratt O**, Tammela T, Isola J, and Visakorpi T. Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer. *Am J Patol* 160:339, 2002.
12. **Bratt O**, Damber J-E, Emanuelsson M, and Grönberg H. Hereditary prostate cancer: clinical characteristics and survival. *J Urol* 167:2423-2426, 2002
13. **Bratt O**: Palliativ cancervård är en betydande del av urologin. Studie av det sista levnadsåret för patienter som dog av urologisk cancer. *Läkartidningen* 99:765-770, 2002.
14. **Bratt O**, Emanuelsson M, and Grönberg H. Psychological aspects of screening in families with hereditary prostate cancer. *Scand J Urol Nephrol*. 37: 5-9, 2003
15. Kvorning N, Beskow A, **Bratt O**, Åkeson J: Patients given acupuncture require more anaesthesia to prevent muscular response to surgical incision. *Acta Anaesthesiol Scand*. 2003 ;47:818-22
16. Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, **Bratt O**, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Törnblom M, Varenhorst E, Johansson JE. Geographical variation in incidence of prostate cancer in Sweden. *Scand J Urol Nephrol*. 2005;39(5):372-9.
17. Wagenius M, Borg Å, Giwercman A, **Bratt O**: CHEK2*1100*delC is not associated with prostate cancer risk in southern Sweden. *Scand J Urol Nephrol*. 2006;40:23-5
18. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelsson A, **Bratt O**, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. *Scand J Urol Nephrol*. 2007, 41:456
19. Stattin P, Holmberg E, **Bratt O**, et al: Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. *J Urol*. 2008, 180:2423
20. Carlsson S, Adolfsson J, **Bratt O**, et al. Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. *Scand J Urol Nephrol*. 2009, 43:350
21. Hagel E, Garmo H, Bill-Axelsson A, **Bratt O**, et al. PCBaSe Sweden: A register-based resource for prostate cancer research, *Scand J Urol Nephrol*. 2009, 43:342
22. Lindberg C, Gudjónsson S, Hilmarsson R, Liedberg F, **Bratt O**. Extended Pelvic Lymphadenectomy for Prostate Cancer: Will the Previously Reported Benefits Be Reproduced in Hospitals with Lower Surgical Volumes? *Scand J Urol Nephrol* 2009, 43:347
23. **Bratt O**, Häggman M, et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. *Br J Cancer* 2009, 101:1233.
24. Bill-Axelsson A, Garmo H, Lambe M, **Bratt O**, et al. Suicide risk in men with Prostate Specific Antigen detected early prostate cancer. *European Urology* 2010, 57:390.
25. van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, **Bratt O**, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: Results from the population-based PCBaSe Sweden. *J Clin Oncol* 2010, 11:450-8
26. **Bratt O**, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P. Prostate Cancer Diagnosed after PSA testing of Men Without Clinical Signs of the Disease -- A Population-based Study from the National Prostate Cancer Register. *Scand J Urol Nephrol* 2010, 44:384-90
27. **Bratt O** & Grenabo L. En stor andel av svenska män har PSA-testats för diagnostik av tidig prostatacancer [in Swedish]. *Läkartidningen* 2010, 7:432-5
28. van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelsson A, Holmberg L, **Bratt O**, et al. Risk of thromboembolic diseases in men with prostate cancer: Results from PCBaSe Sweden. *Lancet Oncol* 2010, 28:3448-56
29. **Bratt O**, Garmo H, Adolfsson J, Bill-Axelsson A, Holmberg L, Lambe M, Stattin P. Effects of Increased Use of PSA Testing on Estimates of Prostate Cancer Risk for Men with a Family History of Prostate Cancer. *J Natl Cancer Inst* 2010, 8:1336-43

Ola Bratt's CV on the 28th April 2024

30. Bill-Axelsson A, Garmo H, Lambe M, **Bratt O**, et al. Psychiatric treatment in men with prostate cancer - Results from a Nation-wide, population-based cohort study from PCBaSe Sweden, *Eur J Cancer*, 2011, 47:2195.
31. Akre O, Garmo H, Adolfsson J, Lambe M, **Bratt O**, Stattin P: Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden. *Eur Urol*, 2011, 60:554.
32. Robinson D, Garmo H, **Bratt O**, et al. Ischemic Heart Disease and Stroke Before and During Endocrine Treatment for Prostate Cancer in PCBaSe Sweden, *Int J Cancer* 2012, 130:278
33. Berglund A, Garmo H, **Bratt O**, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. *Eur J Cancer*. 2012. 48(1):75-84.
34. Kjölhede H, Ahlgren G, Almquist H, ..., and **Bratt O**. Combined F-choline and F-fluoride PET/CT imaging for staging of high risk prostate cancer. *Br J Urol Int*, 2012 Nov;110(10):1501-6
35. Thorstenson A, **Bratt O**, et al. Incidence of fractures causing hospitalization in prostate cancer patients: Results from the population-based PCBaSe Sweden. *Eur J Cancer*, 2012 ;48:1672-81.
36. Jansson F, Akre O, Garmo H, Bill-Axelsson A, Adolfsson J, Stattin P, **Bratt O**. Concordance of tumour differentiation among brothers with prostate cancer. *Eur Urol* 2012 62:656-61
37. **Bratt O**, Lundgren R, Ahlgren G. Systematic PSA screening has been tried in Region Skåne. Balanced information gives chance for equal treatment according to a pilot project [in Swedish]. *Läkartidningen* 2012, Sep 12-18;109(37):1610-2.
38. Carlsson S, **Bratt O**, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: A web-based survey by the Swedish Urology Network. *Scand J Urol Nephrol*. 2012 Dec;46(6):405-10
39. Ladjevardi S, Berglund A, Varenhorst E, **Bratt O**, et al. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11,380 men with serum PSA level 20-100 ng/mL. *BJU Int*. 2013 Mar;111(3):381-8
40. **Bratt O**, Carlsson S, Holmerg E, et al. SAMS: A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. *Scand J Urol* 2013, 47: 347-55
41. Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, **Bratt O**. F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. *World J Urol* 2014, 32: 965-70
42. Loeb S, Folkvaljon S, Makarov DV, **Bratt O**, Bill-Axelsson A, Stattin P. 5 Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer. *Eur Urol* 2015 Feb;67(2):233-8
44. **Bratt O**, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer. *BJU Int*. 2015 Aug;116(2):213-9.
45. Kvorning KT, Jacobsen AK, **Bratt O**, Ahlgren G. Salvage cryotherapy for local recurrence after radiotherapy for prostate cancer. *Scand J Urol*. 2015 Apr;49(2):115-9
46. Kjölhede H, **Bratt O**, Gudjonsson S, Sundqvist P, Liedberg F. Simplified intraoperative sentinel node detection performed by the urologist improves surgical lymph node staging of prostate cancer. *Scand J Urol*. 2015 Apr;49(2):97-102
47. **Bratt O**, Folkvaljon Y, Hjelm-Eriksson M, et al. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. *Eur Urol*. 2015 Jul;68(1):53-8
48. Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, **Bratt O**. 18F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy. *World J Urol*. 2015, 33:1749-52
49. Stattin P, Sandin F, Sandbäck T, Damber JE, **Bratt O**, Lambe M. Dashboard report on performance on select quality indicators to cancer care providers. *Scand J Urol*. 2016 50:21-8.
50. Stattin K, Sandin F, **Bratt O**, Lambe M. The risk of distant metastases and cancer-specific survival in men with serum prostate-specific antigen values above 100 ng/ml. *J Urol* 2015, 194:1594-600
51. Nordström T, **Bratt O**, Örtengren J, Aly M, Adolfsson J, Grönberg H. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. *Scand J Urol* 2015, 50:104-9
52. Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, **Bratt O**, Loeb S, Stattin P, Egevad L. The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012. *BJU Int* 2016, Feb 25. [Epub ahead of print]
53. Hansen N, Patruno G, Wadhwa K, Gaziev G, Miano R, Barrett T, Warren A, **Bratt O (shared last author)**, Kastner C. Magnetic Resonance and Ultrasound Image-Fusion Supported Transperineal Prostate Biopsy using the Ginsburg Protocol: Technique, Learning Points and Biopsy Results. *Eur Urol* 2016, 70:332-40

Ola Bratt's CV on the 28th April 2024

54. **Bratt O**, Drevin L, Akre O, Garmo H, Stattin P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category – a Nationwide Population-based Study. *J Natl Cancer Inst* 2016 Jul 10;108(10).
55. Loeb S, Folkvaljon Y, Robinson D, Makarov DV, **Bratt O**, Garmo H, Stattin P. Immediate versus delayed prostatectomy: Nationwide population-based study. *Scand J Urol*. 2016, 50:246-54
56. Bjartell A, Bottai M, Persson J, **Bratt O**, ..., Akre O. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. *Scand J Urol* 2016, 50:255-9
57. Thorstenson A, Garmo H, Adolfsson J, **Bratt O**. Cancer-specific mortality in men diagnosed with prostate cancer before age 50 years, a nationwide population-based study. *J Urol* 2017, 197:61-66.
58. Stattin P, Sandin F, Thomsen F, Garmo H, Robinson D, Lissbrant I, Jonsson H, **Bratt O**. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. *Eur Urol*. 2017 Jul;72(1):125-134
59. Loeb S, Folkvaljon Y, Curnyn C, Robinson D, **Bratt O**, Stattin P. Uptake of Active Surveillance 2 for Very-Low-Risk Prostate Cancer in Sweden. *JAMA Oncol* 2017 1:1393-1398
60. van Hemelrijck M, Garmo H, **Bratt O**, Stattin P, Adolfsson J. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. *Eur Urol* 2016 72:534-541
61. Hansen N, Barrett T, Koo B, Doble A, Gnanapragasam V, Warren A, Kastner C, **Bratt O**. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. *BJU Int*. 2017, 119:724-730
62. Lamb AD, Thompson S, Kinsella N, ... **Bratt O**, Kastner K. Aiming for a holistic integrated service for men diagnosed with prostate cancer – Definition of standards and skill sets for nursing and allied healthcare professionals. *Eur J Oncol Nurs* 2017 29:31-38
63. Ventimiglia E, Folkvaljon Y, Carlsson S, **Bratt O**, Montorsi F, et al. Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. *J Surg Oncol* 2017 117:321-327
64. Wennick A, Jönsson AK, **Bratt O**, Stenzelius K. Everyday Life after a Radical Prostatectomy – a Qualitative Study of Men Under 65 Years of Age. *Eur J Oncol Nurs* 2017 30:107-112
65. Kjölhede H, Almquist H, Lyttkens K & **Bratt O**. A population-based study of the clinical utility of 18F-choline PET/CT for primary metastasis staging of high-risk prostate cancer. *Eur J Hybrid Imaging* 2017 2:16
66. Robinson D, Garmo H, Franck Lissbrant I, Widmark A, Pettersson A, Gunnlaugsson A, Adolfsson J, **Bratt O**, Nilsson P, Stattin P. Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. *Eur Urol* 2018, 73:502-511
67. Gnanapragasam VJ, **Bratt O**, Muir K, Lee LS, Huang H, Stattin P, Lophatananon L. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: A validation study. *BMC Med* 2018 Feb 28;16(1):31.
68. Jansson F, Drevin L, Frisell T, Stattin P, **Bratt O**, Akre O. Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer. *J Clin Oncol*. 2018, 36:1847-1852
69. Kjölhede H, Almquist H, Lyttkens K, **Bratt O**. Pre-treatment 18F-choline PET/CT is prognostic for biochemical recurrence, development of bone metastasis, and cancer specific mortality following radical local therapy of high-risk prostate cancer. *Eur J Hybrid Imaging* 2018 2:16
70. Barrett T, Reimer F, MacLean MA, **Bratt O**, et al. Quantification of Total and Intracellular Sodium Concentration in Primary Prostate Cancer and Adjacent Normal Prostate Tissue With Magnetic Resonance Imaging. *Invest Radiol* 2018 53:450–456
71. Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelsson A, **Bratt O**, et al. Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. *Eur Urol*. 2018 74:261-280
72. Loeb S, Folkvaljon Y, **Bratt O**, Robinson D, Stattin P. Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance. *J Urol* 2019 201:292-299.
73. Robinson D, Garmo H, Van Hemelrijck M, Damber JE, **Bratt O**, et al. Androgen deprivation therapy for prostate cancer and risk of dementia. *BJU Int* 2019 124:87-92
74. Caglic I, Brzan PP, Warren AY, **Bratt O**, Shah N, Barrett T. Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. *Eur Radiol* 2019 29:5488-5497
75. **Bratt O**, Holmberg E, Andrén O, Carlsson S, Drevin L, Johansson E, Josefsson A, Nyberg M, Sandberg J, Stattin P, Robinson D. The value of an extensive transrectal repeat biopsy with anterior sampling in men on active surveillance for low-risk prostate cancer – a comparison from the randomised Study of Active Monitoring in Sweden (SAMS). *Eur Urol*. 2019 76:461-466.

Ola Bratt's CV on the 28th April 2024

76. Bergengren O, Garmo H, **Bratt O**, et al. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study. *Eur Urol Oncol* 2018 1:37-45.
77. Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, **Bratt O**, Statin P, Muir K, Lophatananon A. Using prognosis to guide inclusion criteria, define standardized end-points and stratify follow up in active surveillance for prostate cancer. *BJU Int* 2019 124:758-767
78. Örtegren J, Holmberg JT... , **Bratt O**, Liedberg F. A randomised trial comparing two protocols for transrectal prostate repeat biopsy: 6 lateral posterior plus 6 anterior cores versus a standard posterior 12-core biopsy. *Scand J Urol* 2019 53(4):217-22
79. Ahlberg MA, Adami HO, Beckmann K, Bertilsson H, **Bratt O**, Cahill D, Egevad L, Garmo H, Holmberg L, Johansson E, Rannikko A, van Hemelrijck M, Jäderling F, Wassberg C, Åberg UWN, and Bill-Axelsson A. PCAST/SPCG-17 – A randomised trial of active surveillance in prostate cancer: rationale and design. *BMJ Open* 2019, Aug 22;9(8):e027860.
80. Christiansen, O; **Bratt, O**; Haug, ES; Vaktskjold, A; Selnes, A; Jordhøy, M. TECLA - an innovative technical approach for prostate cancer registries. *Scand J Urol* 2019 53:229-234
81. Hansen NL, Lloyd T, Warren A, **Bratt O**, Barrett T, Kastner C. Optimizing the number of cores for MRI guided targeted and systematic transperineal prostate biopsy. *BJU Int* 2020 125(2):260-269
82. Stranne J, Axen E, Franck-Lissbrant I, Frånlund M, Hugosson J, Khatami A, Lodding P, Nyberg M, Stattin P & **Bratt O**. Local and national implementation of systematic surgical quality control and feedback for radical prostatectomy services – a 20-year journey. *W J Urol* 2020 38:1397-1411
83. Arnsrud Godtman R, Kjölhede H, Månsson M, **Bratt O**. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: A nationwide population-based study. *Scand J Urol* 2019 53:378-384
84. Bergengren A, Garmo G, **Bratt O**, Holmberg L, Johansson E, Bill-Axelsson A. Determinants for choosing and adhering to active surveillance for localized prostate cancer: a nationwide population-based study. *BMJ Open* 2019, Dec 23;9(12):e033944.
85. **Bratt O**, Drevin L, Prutz KG, et al. Prostate cancer in kidney transplant recipients - a nationwide Swedish register study. *BJU Int*, 2020 125:679-685
86. Jansson F, Folkvaljon F, Stattin P, **Bratt O**, et al. Risk of Postoperative Upstaging or Upgrading Among Men with Low-Risk Familial Prostate Cancer. *J Urol*. 2020 204(1):79-81
87. Thurtle D, **Bratt O**, Stattin P, Pharoah P & Gnanapragasam V. Comparative performance and external validation of the multivariable PREDICT *Prostate* tool for non-metastatic prostate cancer: A study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). *BMC Medicine* 2020 18:139
88. Gunnlaugsson A, Kjellén E, **Bratt O**, et al. PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome – 5 year follow-up of a prospective observational study, *Clinical & Translational Radiation Oncology* 2020 24:23-28
89. Carlsson S, Jäderling F, Kristiansson D, **Bratt O**. The value of a first MRI and targeted biopsies after several years of active surveillance for low-risk prostate cancer – results from the SAMS trial. *Scand J Urol* 2020 54:318-
90. Bergengren O, Enblad AP, Garmo H, **Bratt O**, Holmberg L, Johansson E & Bill-Axelsson A. Changes in lifestyle among prostate cancer survivors: a nationwide population-based study. *Psycho-oncology*, 2020 Aug 10.doi: 10.1002/pon.5513
91. Christiansen O, Benth JS, Kirkevold O, **Bratt O**, Slaaen M. Construct validity of the questionnaire Quality from the Patients Perspective adapted for surgical prostate cancer patients. *J Patient Exper*, March 2021 (<https://doi.org/10.1177/2374373521998844>)
92. Fallara F, Sandin F, Styrke J, Carlsson S, Lissbrant IF, Ahlgren J, **Bratt O**, Lambe M & Stattin P. Prostate cancer diagnosis, staging, and treatment during the first phase of the COVID-19 pandemic, *Scand J Urol* 2021 55:184-191
93. Ternov KK, Nolsøe AB, **Bratt O**, et al. Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2021;24:948-961
94. Forsvall A, Fisher J, Cardoso JFP, Wagenius M, Tverring J, Bo Nilson B, Dahlin A, **Bratt O**, Linder A, Mohanty T. Evaluation of the Forsvall biopsy needle in an ex vivo model of transrectal prostate biopsy - A novel needle design with the objective to reduce the risk of post-biopsy infection. *Scand J Urol* 2021;55:227-234
95. Forsvall A, Fisher J, Wagenius M, Broman C, Korkocic D, Nilson B, **Bratt O** & Linder A. Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial. *Scand J Urol* 2021;55:235-41
96. Forsvall A, Jönsson H, Wagenius M, **Bratt O** & Linder A. Rate and characteristics of infection after transrectal prostate biopsy – a retrospective observational study. *Scand J Urol* 2021;55:317-22

Ola Bratt's CV on the 28th April 2024

97. Christiansen O, **Bratt O**, Kirkevold Ø, Benth JS, Manoharan P, Selnes A, Haug ES, Slaaen M. Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging. *C Eur J Urol* 2022;75:35-40
98. Christiansen O, Kirkevold Ø, **Bratt O**, Benth JS, Slaaen M. Experience Measures after Radical Prostatectomy: A Register-Based Study Evaluating the Association between Patient-Reported Symptoms and Quality of Information. *Healthcare* 2022;10:519
99. Miah S, Maw J, Pang K, Nair V, Hori S, Lamb A, **Bratt O**, et al. The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision. *Urol Ann* 2022;14:156-61.
100. Stenman C, Abrahamsson E, Redsäter M, Gnanapragasam VJ, **Bratt O**. Rates of Positive Abdominal Computed Tomography and Bone Scan Findings Among Men with Cambridge Prognostic Group 4 or 5 prostate cancer: A Nationwide Registry Study. *Eur Urol Open Sci* 2022; 41: 123-5
101. Alterbeck M, Järbur E, Thimansson E, Wallström J, Bengtsson J, Björk-Eriksson T, Bjartell A, **Bratt O**, Jiborn T, Arnsrud Godtman R. Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme. *Eur Urol Focus*. 2022 Nov;8(6):1568-1574
102. Gunnlaugsson A, Johannesson V, Wieslander E, Brun E, Bitzen U, Ståhl O, **Bratt O**, Ahlgren G, Ohlsson T, Kjellén E, Nilsson P. A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and ⁶⁸Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial. *Clin Transl Radiat Oncol*. 2022; 36:77-82.
103. Ventimiglia E, Bill-Axelsson A, **Bratt O**, Montorsi F, Stattin P, Garmo H. Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden. *JAMA Netw Open*. 2022; 5(9):e2231015.
104. Örtengren J, Wimmerstedt A, ..., **Bratt O**. Clinical Value of a Routine Urine Culture Prior to Transrectal Prostate Biopsy. *Eur Urol Open Sci*. 2022; 48:54-59
105. Svensson L, Stinesen Bratt K, Jiborn T, Börjedahl AC, **Bratt O**. Men's perception of being invited for prostate cancer testing and the information about its pros and cons - a survey from two population-based testing programmes. *Eur Urol Open Sci*. 2023; 52:66-71
106. Bjerner J, **Bratt O**, ... Oldenburg J. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. *Eur Urol* 2023 May 9:S0302-2838(23)02791-4
107. Jakobsson RG, Nasic S, **Bratt O**, Johansson ME, Bergdahl AG. Family History and Risk of Renal Cell Carcinoma: A National Multiregister Case-Control Study. *J Urol*. 2023 (online publ Nov).
108. **Bratt O**, Godtman RA, Jiborn T, et al.. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. *Eur Urol*. 2024 85:207-214
109. Strömberg U, Berglund A, ..., & **Bratt O**. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. *Int J Cancer* 2024 (online 25th March 2024)
110. Dang H, Huang V, **Bratt O**. Normalised repeat serum prostate-specific antigen: associations with age and magnetic resonance imaging results. *Scand J Urol*. 2024 Mar 6;59:54-57
111. Lundberg F, Robinson D, **Bratt O**, Fallara G, Lambe M, Johansson ALV. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. *Acta Oncol*. 2024 Mar 20;63:95-104

Review articles

1. **Bratt O**. Hereditary prostate cancer. *Br J Urol International*, 85:588-598, 2000.
2. **Bratt O**. Aspectos clínicos del cáncer de próstata hereditario. *Rev Urol* 2001, 2: 37-42
3. **Bratt O**. Hereditary prostate cancer. Clinical aspects. *Review Series, Urology*, 3:2-6, 2001
4. **Bratt O**. Hereditary prostate cancer: clinical aspects. *J Urol* 168: 906-913, 2002.
5. **Bratt O**. Prostatocancer. *Incitament*, 43-47, 2006
6. **Bratt O**. Low dose-rate interstitial brachytherapy with permanent seeds implants for localised prostate cancer. *Review Series, Urology*, 2006
7. **Bratt O**. The Urologist's Guide to Low Dose-rate Interstitial Brachytherapy with Permanent Seeds Implants for Localised Prostate Cancer. *BJU Int*. 99:743-7, 2007
8. **Bratt O**. What Should a Urologist Know about Hereditary Predisposition for Prostate Cancer? *BJU Int*. 99:497-501, 2007
9. **Bratt O** & Björk T: PSA – vår mest värdefulla cancermarkör, *Läkartidningen* nr 46 2007

Ola Bratt's CV on the 28th April 2024

10. **Bratt O**, Damber, J-E, Kärvinge C, et al.: Hälsokontroll med PSA-test för tidig upptäckt av prostatacancer: en nationell informationsbroschyr framtagen, Läkartidningen nr 8 2008
11. **Bratt O**. Socialstyrelsens PSA-broschyr sprids nu över Sverige – vad kommer detta att medföra? Onkologi i Sverige, nr 2 2008
12. **Bratt O**. Osteoporos vid kastrationsbehandling för prostatacancer. Incitament nr 1 2009
13. Holmström B, Johansson M, **Bratt O**, Stattin P. PSA-testet håller inte för screening. Bra - men inte tillräckligt bra. Läkartidningen 2010, 7:436-9
14. **Bratt O**. Urologin i Nordvästskåne (redaktör för temanummer), Incitament 2011
15. **Bratt O**. Prostatacancer, Incitament 2011
16. **Bratt O** & Schumacher MC. Natural history of prostate cancer, chemoprevention and active surveillance. Acta Oncol 2011, 50 Suppl 1:116-9
17. **Bratt O** & Åkesson K. Osteoporosis after castration treatment of prostate cancer. Läkartidningen 2011, 108:1902
18. **Bratt O**, Damber J-E, Aldehag A, Brändström H. Prostatacancer – nationellt vårdprogram och nya nationella riktlinjer, Läkartidningen 2015 Jan 27;112. pii: C6XC
19. **Bratt O**, Lilja H. Serum markers in prostate cancer detection. Curr Op Urol 2015 Jan;25(1):59-64
20. **Bratt O**. MRI for the detection of prostate cancer [in Swedish]. Läkartidningen 2015 Apr 20;112.
21. **Bratt O**. Nya rön om ärftlighet och prostatacancer, Onkologi i Sverige, nr 3 2016
22. **Bratt O**, Ahlgren G, Börjedahl A-C, Lissbrant I, Waller C. Prostate cancer units - hubs in the future care of men with prostate cancer [in Swedish]. Läkartidningen, February 2017
23. **Bratt O**. Paradigmskifte för prostatacancerdiagnostik, Onkologi i Sverige, nr 1 2020
24. **Bratt O**. Organiserad prostatacancerdiagnostik – var står vi idag? Onkologi i Sverige, nr 3 2022
25. **Bratt O**, Carlsson S, Fransson P, ..., Kindblom J, Swedish National Prostate Cancer Guidelines Group. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022 July 11:1-9
26. **Bratt O**, Carlsson S, Fransson P, Kindblom J, Stranne J, Karlsson CT; Swedish National Prostate Cancer Guidelines Group. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022 July 7:1-7.
27. **Bratt O**, Auvinen A, Arnsrud Godtman R, Hellström M, Hugosson J, Lilja H, Roobol M. Screening for prostate cancer – evidence, ongoing trials, policies and knowledge gaps, BMJ Oncol 2023 2023;2:e000039.
28. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023 84:191-206.
29. Vickers A, O'Brien F, Montorsi F, Galvin D, **Bratt O**, et al. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. BMJ. 2023 17;381:e071082.
30. Arnsrud Godtman R, **Bratt O**, Nordström T, Wallström J, Hugosson J. Prostate cancer - diagnostics and screening. Läkartidningen (Swedish Medical Journal), 2024 121:421-423
31. Stranne J, Carlsson S, Gunnlaugsson A, Kindblom J, Lantz A, **Bratt O**. Treatment of non-metastatic prostate cancer. Läkartidningen (Swedish Medical Journal), 2024 121:424-427
32. Lewén K, Waller C, Grönberg H, **Bratt O**. Prostate cancer from the patients' perspective. Läkartidningen (Swedish Medical Journal), 2024 121:421-423

Editorials, etc

1. **Bratt O**, Abrahamsson P-A, Lundgren R, Olsson H och Kristofferson U: Forskningsframsteg om hereditär prostatacancer. Medicinsk kommentar, Läkartidningen, 95:1494, 1998.
2. **Bratt O**. The Difficult Case in Prostate Cancer Diagnosis-When is a "Diagnostic TURP" Indicated? Eur Urol. 2006 May;49(5):769-71
3. **Bratt O**. Watching the Face of Janus - Active Surveillance as a Strategy to Reduce Over-treatment for Localised Prostate Cancer. Eur Urol. 50:410-12 2006
4. **Bratt O**. Myndighet i USA avråder från prostatacancerscreening. Hur påverkas svenska riktlinjer? Medicinsk kommentar, Läkartidningen 2011, 46:2362
5. Liedberg F, Ahlgren G, **Bratt O**, Bendahl PO. A plea for surgical lymph node staging in advanced prostate

Ola Bratt's CV on the 28th April 2024

cancer. *Eur Urol.* 2013 Feb;63(2):409-10.

6. **Bratt O.** The clinical impact of genetic susceptibility to prostate cancer. *Eur Urol.* 2014 Sep;66(3):500-1

7. **Bratt O,** Loman N. Clinical Management of Prostate Cancer in Men with BRCA Mutations. *Eur Urol.* 2015 Aug;68(2):194-5.

8. Lamb AD, **Bratt O.** Towards "next-generation" prostate cancer screening. *Lancet Oncol.* 2015 Dec;16(16):1579-80.7

9. **Bratt O,** Hugosson J, Klotz L, Gnanapragasam V. The drama of prostate cancer diagnostics. *Lancet Oncol.* 2017 Mar;18(3):e132.

10. Larsson LT, Kain J, **Bratt O.** Socialstyrelsen: Mer forskning behövs för förbättrad diagnostik av prostatacancer. *Läkartidningen.* 2018 Feb 13;115. pii: E3F4

11. **Bratt O.** Paradigmskifte inom prostatacancerdiagnostik, *Läkartidningen,* October 2019

12. **Bratt O.** Has the time come for routine use of PET/CT for guiding treatment of biochemical recurrence after radical prostatectomy? *Scand J Urol.* 2021 Oct;55(5):420-421.

13. **Bratt O** & Lilja H. Modern prostate cancer diagnostics reduce overdiagnosis - will they open up for population-based screening? *Scand J Urol.* 2021 Dec;55(6):491-492.

14. **Bratt O.** Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making. *BJU Int.* 2022 Jan;129(1):3-4

15. **Bratt O.** Is it time to abandon prophylactic antibiotics for transperineal prostate biopsy. *Lancet Inf Dis* 2022 Jul 12:S1473-3099(22)00419-4.

16. Iczkowski KA, Molina M, Egevad L, Bostwick DG, ..., **Bratt O,** ... Delahunt B. Low-grade prostate cancer should still be labelled cancer. *BJU Int.* 2022 Dec;130(6):741-743

17. **Bratt O.** The Long and Winding Road from Guideline Recommendations to Improved Quality of Care. *Eur Urol.* 2023 83(5):402-404

18. **Bratt O,** Auvinen A. First diagnostic results from Gothenburg-2 screening trial. *Scand J Urol.* 2023

19. **Bratt O,** Auvinen A. Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. *Eur Urol.* 2023 Apr;83(4):370-371.

20. **Bratt O.** A note on the importance of wording. *Eur J Prev Cardiol.* 2023 Aug 16:zwad269.

21. **Bratt O.** Evidensbaserad screening för prostatacancer börjar ta form. *Läkartidningen (Swedish Medical Journal).* 2023 120:231.

22. Májek O, Babjuk M, Roobol MJ, **Bratt O,** et al. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration. *Eur Urol O Sci.* 2023 8;53:106-108

23. **Bratt O.** First population-level results of pre-biopsy prostate MRI. *Scand J Urol.* 2023 Sep 28;58:84-85.

24. **Bratt O.** Screening for Prostate Cancer With Modern Diagnostics-Another Piece of the Puzzle. *JAMA Netw Open.* 2024 Feb 5;7(2):e2354544.

25. **Bratt O.** Prostate Cancer – a Disease in Transformation. *Läkartidningen (Swedish Medical Journal),* 2024 121:419-420

Books and book chapters

Att leva med prostatacancer (book 34 pages), O Bratt, 2008, revised and reprinted 2012

Sex, samliv och prostatacancer (book 88 pages), CD Jägervall & O Bratt, 2019

Urologi (chapter, 32 pages), with co-author H Thulin, in Rystedt J & Wann-Hansson C (Editors): *Omvårdnad & kirurgi. Studentlitteratur.* Lund, 2016

Urologi (chapter, 36 pages), with co-author H Thulin, in Rystedt J & Wann-Hansson C (Editors): *Omvårdnad & kirurgi. Studentlitteratur.* Lund, 2022

Urologi (chapter, 50 pages), with co-author Professor F Liedberg, in P Naredi (Editor): *Kirurgi, Studentlitteratur.* Lund, 2020

Prostate cancer (chapter, 8 pages) in *Cancersjukdomar, Studentlitteratur.* Lund, 2023

Prostate cancer screening (chapter, 2 pages) in *Cancersjukdomar, Studentlitteratur.* Lund, 2023

Ola Bratt's CV on the 28th April 2024

Bra att veta om prostatacancer - Sveriges vanligaste cancersjukdom (book, 187 pages), with co-authors Ingela Lissbrant, Elisabet Skeppner and Carina Jägervall. Prostatacancerförbundet. Stockholm 2023.

Epidemiology of Prostate Cancer (Chapter member of a 32-page book chapter), in Localised Prostate Cancer (International Consultation of Urological Disease), Delhi 2024

Screening and Early Detection of Prostate Cancer (Chapter chair of a 39-page book chapter), in Localised Prostate Cancer (International Consultation of Urological Disease), Delhi 2024